Congrès internationaux

26th European Congress of Clinical Microbiology and Infectious Diseases ECCMID 2016 9-12 April 2016 Amsterdam, Netherlands    

Pierre Loulergue, Angèle Soria, Hélène Perrin, Alexandra Rousseau, Olivia Bonduelle, Marine Cachanado, Lilia Benslama, Mélody Dufossée, Annika Vogt, Sylvie Van Der Werf, Sylvie Behillil, Tabassome Simon, Behazine Combadière,Odile Launay Projet : Fluway-V2

Local skin reactions as potential indicators ofvaccine-specific memory CD8+ T cell immune responses to influenza vaccination

26th European Congress of Clinical Microbiology and Infectious Diseases ECCMID 2016 9-12 April 2016 Amsterdam, Netherlands 

Minh P Lê, Linda Belarbi, Gilles Peytavin,Marie-Laure Chaix, Emmanuel Dulioust, Nadia Mahjoub, Dominique Salmon,Jean-Paul Viard, Odile Launay, JadeGhosn

Diffusion et efficacité demaraviroc, raltégravir et rilpivirine dans les fluides génitaux de patientsinfectés par le VIH (étudeRAMAVAC)

8ème Conférence Internationale francophone VIH/Hépatites AFRAVIH 2016 20-23 avril 2016 Bruxelles, Belgique

R. Ho Tsong Fang1, O.Launay2, C. Rouzioux5, B. Autran3, J. Capeau4, A. Melard5, M. Marcu1, R.Calin6, H. Bodilis2, J. Crouzet1, V. Vieillard7, P. Debre7, S. Gharakhanian8,C. Katlama9 

VAC-3S, a safeImmunotherapeutic HIV Vaccine decreased total HIV DNA and increased CD4/CD8ratio: Phase I Final Results.

4th European Congress of Immunology – ECI 2015.Vienna, September 6–9, 2015 .

​Blok H. Perrin, A. Soria, P. Loulergue,A. Rousseau, O. Bonduelle, M. Cachanado, L. Ben Slama, M. Dufossee, A.Vogt, S. Van Der Werf, S. Behilli, T. Simon, O. Launay, B. Combadiere.

Local skin reactions as potential indicators of vaccine-specific memory CD8+ T-celle Immune responses to influenza vaccination

2015 IAS Towards an HIV Cure Symposium 18 & 19 July 2015, Vancouver, Canada.

Loubet P, Kernéis S, Groh M, Loulergue P, Blanche P, Launay O

Determinants of influenza and pneumococcal vaccination among patients with secondary immune deficiency

25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 25–28 April 2015 Copenhagen, Denmark

M. Bahuaud , M. Malphettes , H. Bodilis , S.Park , D. Bouscary , F. Batteux , O. Launay , J.P. Fermand

Immunogenicity of the 13-valent pneumococcal conjugate vaccine (pcv13) in patients with untreated smoldering multiple myeloma (mm) : a pilot study

9th International Symposium on Pneumococci andPneumococcal Diseases (ISPPD) India March 9-13, 2014

Sophie Grabar, PierreTattevin, Hana Selinger-Leneman, Arnaud de la Blanchardiere, Christian Rabaud,David Rey, Vincent Daneluzzi, Samuel Ferret, Dominique Costagliola, Odile Launay

Early Impact of cART on the Risk of Herpes Zoster: Results From the FHDH-ANRS CO4

21st Conference on Retroviruses and Opportunistic Infections (CROI), March 3-6, 2014² Boston, Massachusetts

Corinne Desaint, Christine Durier, Jean-Daniel Lelièvre,Benjamin Silbermann, Gilles Pialoux, Lise Cuzin, Isabelle Poizot-Martin, Pascale Morineau, Amel Bouakane, Bruno Spire, Yves Lévy, Jean-Pierre Aboulker, Odile Launay

Update of the Long-term Follow-up of Healthy Volunteers from Preventive HIV-1 VaccineTrials: ANRS COV1-COHVAC Cohort

HIV Research For Prevention Conference 2014, CapeTown (South Africa), 28-31 October 2014

Costagliola D, Lacombe JM, Ghosn J2, Delaugerre C, Pialoux G, Cuzin L, Launay O, Ménard A, de Truchis P, Mary-Krause M, Weiss L, Delfraissy JF

CD4+ cell count recovery in naïve patients initiating cART, who achievedand maintained plasma HIV-RNA suppression

HIV Drug TherapyGlasgow Congress 2014, 2-6 november 2014

Loulergue P1, Pulcini C, Massin S, Bernhard M, Fonteneau L, Levy-Brühl D, Guthmann JP, Launay O.

Validity of self-reported vaccination status among French healthcare students

23rd European Congress ofClinical Microbiology and Infectious Diseases (ECCMID) Berlin, Germany: 27-30April 2013

Katlama Ch, Launay O, Ho Tsong Fang R, BodilisH, Calin R, Autran B,  Gharakhanian S, Vieillard V, J Crouzet J, Debré P.

Arandomized, placebo-controlled, double-blind, phase I/IIa dose escalation study of an HIV immunotherapeutic vaccine, VAC-3S, directed to the gp41 3S motif ofHIV-1

20th Conference onRetroviruses and Opportunistic Infections (CROI), Atlanta, GA, USA, 3-6 March 2013

Crouzet J, Vieillard V, Debré P, Katlama C,Launay O, Ho Tsong Fang R, Desfontaines-Batéjat D, Marcu M, Gharakhanian S

Potential role of anti-3S antibodies in an HIV medical cure strategy ?

HIV Cure & Eradication Workshop, 24-25 January 2013; Milan, Italy.

Gharakhanian S, C Katlama C, LaunayO, Bodilis H, Calin R, R Ho Tsong Fang R, Marcu M, Autran B, Vieillard V, Crouzet J P Debré

VAC-3S,an Immunoprotective HIV Vaccine Directed to the 3S Motif of gp41, in Patients Receiving ART: Safety, Dose & Immunization Schedule Assessment.

AIDS Vaccine 2013 Conference, 7-10 October,Barcelona, Spain

C Katlama, O Launay , S Gharakhanian , R HoTsong Fang , B Autran  , V Vieillard, JCrouzet, R Murphy , PDebré

Experimental Evidence and Potential Immunotherapeutic Applications of Vaccine-Induced Antibodies Against 3S, a Highly Conserved Motif of gp41, in HIV-1-infected Patients Treated with Antiretroviral Therapy.

"30 years of HIV science: Imagine thefuture" Institut Pasteur (Paris) on21-23 May 2013

Rondy M, Puig-Barbera J, Launay O, Duval X, Castilla J, Guevara M, Costanzo S, de Gaetano Donati K, Moren A. 

2011-12seasonal influenza vaccines effectiveness against confirmed A(H3N2) influenzahospitalisation: pooled analysis from a European network of hospitals. A pilotstudy.

6th European Scientific Conference on Applied Infectious Disease Epidemiology (ESCAIDE)

Edinburgh Scotland UK: 24-26 October 2012 

Freund R, Krivine A, Prévost V, Cantin D, Aslangul E, Avril MF, Claessens YE, Rozenberg F, Casetta A, Baixench MT, Dumaine V, Launay O, LoulergueP.

Measlesimmunity and measles vaccine acceptance among healthcare workers in Paris,France

22nd European Congressof Clinical Microbiology and Infectious Diseases (ECCMID) London, UK: 31March-3 April 2012

Launay O1, Le Strat Y, Tosini W, Kara L, Quelet S, Lévy S, Danan J, Réveillon J, Houdayer J, Bouvet E, Lévy-Bruhl D; ANRS-FORMVAC Study Group.

Impact of Free HBV Vaccination and/or Healthcare Workers Training on Vaccine Acceptability in High Risk Subjects –ANRS FORMAC Trial

52nd Interscience Conference on AntimicrobialAgents and Chemotherapy (ICAAC) San Francisco,California USA: 9 – 12 September 2012.

Loulergue P, Roussseau B, Mir O, Viel E, Krivine A, Goldwasser F, de Gramont A, Launay O, Tournigand C.
 Immunogenicity and safety of two doses of AS03A-adjuvanted influenza A H1N1v 2009 vaccine in cancer patients on chemotherapy - VACANCE study. 
 21^th ECCMID, Milan, May 7-10, 2011.

Durier C, Desaint C, Colin de Verdière, Girard PM, Lévy Y, Rey D, Jacomet C, Lucht F, Aboulker JP, Launay O,
for the ANRS 151 study group and the REIVAC network.
Durier C, Desaint C, Silbermann B, Lelièvre JD, Slama L, Morineau-Le Houssine P, Cuzin Lise, Poizot-Martin, Aboulker J P, Launay O
for the ANRS COV1-COHVAC Study Group.
 Durability of the Immune Response after Vaccination with Two Doses of Influenza A H1N1v 2009 Vaccine Formulated with and without AS03A-Adjuvant in HIV-infected Adults: the ANRS 151 Randomized HIFLUVAC Trial. Long term vaccine-induced HIV seropositivity amoung HIV uninfected healthy volunteers in ANRS COV1-COHVAC cohort.
 18^th Conference on Retroviruses and Opportunistic Infections; Boston; February 27-March 2, 2011